SMAD2 (Ab-220) Antibody

What is the epitope specificity of SMAD2 (Ab-220) Antibody?

SMAD2 (Ab-220) Antibody recognizes a peptide sequence around amino acids 218-222 (P-E-T-P-P) derived from Human SMAD2. This antibody was produced by immunizing rabbits with a synthetic peptide conjugated to KLH and subsequently purified by affinity-chromatography using the epitope-specific peptide . The antibody detects endogenous levels of total SMAD2 protein across multiple species, including human, mouse, and rat samples .

What experimental applications is SMAD2 (Ab-220) Antibody validated for?

SMAD2 (Ab-220) Antibody has been validated for Western Blot (WB) and Immunohistochemistry (IHC) applications . For Western blotting, the antibody effectively detects the endogenous SMAD2 protein at approximately 52-65 kDa . When comparing to other commercially available SMAD2 antibodies, such as AF6497, which is additionally validated for immunofluorescence/immunocytochemistry (IF/ICC) , researchers should select the appropriate antibody based on their specific experimental needs and required applications.

What are the optimal sample preparation conditions for detecting SMAD2 using this antibody in Western blot applications?

For optimal Western blot results with SMAD2 (Ab-220) Antibody, cells or tissues should be lysed in buffer containing phosphatase inhibitors, especially when studying TGF-β signaling dynamics. The antibody works effectively with samples denatured in standard SDS-PAGE loading buffer containing DTT or β-mercaptoethanol. Based on the properties of SMAD2 protein, samples should be resolved on 10-12% polyacrylamide gels for optimal separation of the 52-65 kDa target protein . Transfer to PVDF or nitrocellulose membranes should be performed at 100V for 60-90 minutes in standard Towbin buffer. For blocking, 5% non-fat dry milk in TBST is recommended, followed by primary antibody incubation at 1:1000 dilution overnight at 4°C. This methodology ensures consistent detection of total SMAD2 protein while minimizing background signal.

How should researchers optimize immunohistochemistry protocols when using SMAD2 (Ab-220) Antibody?

For immunohistochemistry applications with SMAD2 (Ab-220) Antibody, researchers should implement the following optimization steps: (1) Test multiple antigen retrieval methods, including citrate buffer (pH 6.0) and EDTA buffer (pH 8.0), as SMAD2 epitope accessibility can vary between tissue types and fixation conditions; (2) Perform antibody titration experiments testing dilutions between 1:100-1:500 to determine optimal signal-to-noise ratio; (3) Include appropriate positive control tissues known to express SMAD2 (such as skeletal muscle, endothelial cells, heart and placenta tissues) ; (4) Implement proper negative controls by omitting primary antibody or using non-immune rabbit IgG; (5) Consider signal amplification systems for tissues with low SMAD2 expression levels. This methodical approach ensures reliable and reproducible IHC results when investigating SMAD2 protein localization and expression patterns in different tissues.

What are the recommended controls when studying SMAD2 phosphorylation dynamics?

When investigating SMAD2 phosphorylation dynamics, researchers should implement multiple control conditions to ensure experimental validity: (1) Use both total SMAD2 antibodies like SMAD2 (Ab-220) and phospho-specific antibodies in parallel to normalize phosphorylation to total protein levels ; (2) Include positive controls by treating cells with TGF-β (5-10 ng/ml for 30-60 minutes) to induce SMAD2 phosphorylation; (3) Implement negative controls using TGF-β receptor inhibitors (such as SB431542) to block phosphorylation; (4) Consider time-course experiments to capture the transient nature of SMAD2 phosphorylation events; (5) Include loading controls such as GAPDH or β-actin for normalization across samples. For advanced studies, phosphorylation-deficient SMAD2 mutants (S250A) can serve as additional negative controls when overexpressed in cell models .

How can researchers address weak or absent SMAD2 signal in Western blot experiments?

When encountering weak or absent SMAD2 signal in Western blot experiments using SMAD2 (Ab-220) Antibody, researchers should systematically troubleshoot using the following approach: (1) Verify protein loading by staining membranes with Ponceau S or using housekeeping protein controls; (2) Increase protein loading to 30-50 μg per lane for cell lysates with potentially low SMAD2 expression; (3) Optimize antibody concentration by testing dilutions between 1:500-1:2000; (4) Extend primary antibody incubation to overnight at 4°C to enhance binding; (5) Implement more sensitive detection methods such as enhanced chemiluminescence (ECL) substrates with longer exposure times; (6) Verify sample preparation by ensuring complete protease inhibition during lysis; (7) Check transfer efficiency using pre-stained molecular weight markers. Additionally, since SMAD2 can undergo degradation in certain signaling contexts , researchers should consider the activation state of degradation pathways in their experimental models.

What strategies can address non-specific binding or high background when using this antibody?

To address non-specific binding or high background when using SMAD2 (Ab-220) Antibody, researchers should implement the following optimization strategies: (1) Increase blocking stringency by using 5% BSA instead of milk, or by extending blocking time to 2 hours at room temperature; (2) Add 0.1-0.3% Triton X-100 to antibody dilution buffers to reduce hydrophobic interactions; (3) Increase washing duration and frequency (5-6 washes, 10 minutes each); (4) Pre-adsorb the antibody with non-specific proteins by diluting in blocking buffer containing 5% serum from the species of the secondary antibody; (5) Reduce secondary antibody concentration or switch to more specific detection systems; (6) For tissues with high endogenous peroxidase activity, implement additional quenching steps. These methodological adjustments can significantly improve signal specificity while reducing background interference in both Western blot and immunohistochemistry applications.

How should researchers validate antibody specificity for SMAD2 versus related SMAD family members?

Validating SMAD2 (Ab-220) Antibody specificity against other SMAD family members requires a multi-faceted approach: (1) Perform side-by-side Western blots comparing lysates from cells with SMAD2 knockdown/knockout against wild-type cells; (2) Use recombinant SMAD2, SMAD3, and SMAD4 proteins as controls to assess cross-reactivity; (3) Implement peptide competition assays using the immunizing peptide (aa.218-222) to confirm epitope specificity; (4) Utilize overexpression systems with tagged SMAD family members to assess potential cross-reactivity through parallel detection with tag-specific antibodies; (5) Consider immunoprecipitation followed by mass spectrometry to identify all proteins captured by the antibody. This comprehensive validation approach ensures that experimental results genuinely reflect SMAD2-specific biology rather than cross-reactivity with structurally similar SMAD family proteins.

How can SMAD2 (Ab-220) Antibody be used to investigate the relationship between linker region phosphorylation and protein stability?

SMAD2 (Ab-220) Antibody can be strategically employed to investigate the relationship between linker region phosphorylation and protein stability through several advanced approaches: (1) Conduct parallel Western blots using SMAD2 (Ab-220) Antibody and phospho-specific antibodies (such as pThr220 or pSer250) to monitor total protein levels versus phosphorylation status; (2) Implement cycloheximide chase assays comparing wild-type SMAD2 degradation kinetics against phosphorylation-deficient mutants (S250A) and phosphomimetic mutants (S250D) ; (3) Combine with ubiquitination assays to correlate phosphorylation states with ubiquitin-mediated degradation; (4) Perform co-immunoprecipitation experiments to identify phosphorylation-dependent interaction partners that regulate SMAD2 stability; (5) Use the antibody in pulse-chase experiments to determine protein half-life under different signaling conditions that affect phosphorylation. These methodologies can provide mechanistic insights into how linker region phosphorylation by kinases like NLK promotes SMAD2 degradation and modulates TGF-β signaling intensity .

What experimental design would effectively demonstrate the functional consequences of SMAD2 phosphorylation at T220 versus other phosphorylation sites?

To effectively demonstrate the functional consequences of SMAD2 phosphorylation at T220 compared to other sites, researchers should implement a comprehensive experimental design: (1) Generate cell lines expressing phosphorylation-deficient SMAD2 mutants (T220A, S250A, S465/467A) in SMAD2-knockout backgrounds; (2) Perform parallel Western blots using SMAD2 (Ab-220) Antibody to monitor total protein levels alongside phospho-specific antibodies for each modification site ; (3) Assess transcriptional activity using SMAD-responsive luciferase reporters (e.g., SBE4-luc) across mutant variants; (4) Conduct chromatin immunoprecipitation (ChIP) assays to determine how each phosphorylation site affects SMAD2 binding to target gene promoters; (5) Analyze nuclear/cytoplasmic fractionation to determine how different phosphorylation events affect subcellular localization; (6) Perform protein turnover studies to correlate specific phosphorylation events with degradation rates; (7) Use proximity ligation assays to detect phosphorylation-dependent protein-protein interactions. This multi-faceted approach would provide mechanistic insights into how different phosphorylation events uniquely contribute to SMAD2 function in TGF-β signaling.

How can researchers design experiments to distinguish between total SMAD2 levels and phosphorylation-dependent signaling activity?

Researchers can design experiments to distinguish between total SMAD2 levels and phosphorylation-dependent signaling activity through the following methodological approach: (1) Perform simultaneous Western blots on cellular fractions using SMAD2 (Ab-220) Antibody to detect total protein alongside phospho-specific antibodies targeting C-terminal (pS465/467) and linker region phosphorylation sites (pT220, pS250) ; (2) Implement time-course experiments following TGF-β stimulation to track the relationship between phosphorylation dynamics and total protein levels; (3) Utilize immunofluorescence with dual labeling to simultaneously visualize total SMAD2 distribution and specific phospho-SMAD2 populations within individual cells; (4) Conduct transcriptional reporter assays in parallel with protein analysis to correlate signaling activity with specific phosphorylation patterns; (5) Apply phosphatase inhibitors selectively to maintain specific phosphorylation events while blocking others; (6) Employ mass spectrometry to quantitatively assess the stoichiometry of different phosphorylation events relative to total SMAD2 levels. This integrated approach enables researchers to distinguish between changes in SMAD2 expression versus alterations in its activation state, providing deeper insights into TGF-β signaling regulation.

How should researchers interpret conflicting results between total SMAD2 detection and phospho-specific SMAD2 antibody signals?

When encountering conflicting results between total SMAD2 detection using SMAD2 (Ab-220) Antibody and phospho-specific SMAD2 antibody signals, researchers should consider several interpretative frameworks: (1) Evaluate the possibility of phosphorylation-dependent epitope masking, where certain phosphorylation events might alter protein conformation and affect antibody accessibility to the Ab-220 epitope region; (2) Consider phosphorylation-induced protein degradation mechanisms, as research indicates that linker region phosphorylation (e.g., at S250) promotes SMAD2 degradation ; (3) Assess compartmentalization effects, as phosphorylated SMAD2 may localize to specific cellular compartments that might be extracted differently during sample preparation; (4) Implement dephosphorylation assays using lambda phosphatase treatment on duplicate samples to normalize detection conditions; (5) Verify results using multiple antibody combinations targeting different SMAD2 epitopes and phosphorylation sites. This systematic approach helps distinguish between technical artifacts and genuine biological phenomena related to SMAD2 regulation in TGF-β signaling contexts.

What quantitative methods are most appropriate for analyzing SMAD2 phosphorylation dynamics in relation to total protein levels?

For quantitative analysis of SMAD2 phosphorylation dynamics relative to total protein levels, researchers should implement the following methodological approaches: (1) Perform densitometric analysis of Western blots using SMAD2 (Ab-220) Antibody alongside phospho-specific antibodies, calculating phospho/total ratios for each time point or condition; (2) Apply non-linear regression models to phosphorylation kinetics data to determine rate constants for both phosphorylation and subsequent dephosphorylation; (3) Implement pulse-chase labeling combined with immunoprecipitation to determine how phosphorylation affects protein half-life; (4) Use high-content imaging with ratiometric analysis of total versus phospho-SMAD2 immunofluorescence signals at the single-cell level; (5) Apply mathematical modeling approaches such as ordinary differential equations to integrate multiple phosphorylation events with protein degradation rates; (6) Consider Förster resonance energy transfer (FRET)-based biosensors for real-time monitoring of SMAD2 phosphorylation states in living cells. These quantitative methods allow researchers to precisely determine how different stimuli affect both the magnitude and temporal dynamics of SMAD2 phosphorylation relative to total protein levels.

How do findings from SMAD2 (Ab-220) Antibody studies integrate with our understanding of TGF-β pathway regulation in disease contexts?

Findings from SMAD2 (Ab-220) Antibody studies integrate with our understanding of TGF-β pathway regulation in disease contexts through several mechanistic frameworks: (1) The detection of total SMAD2 protein levels across different tissue contexts helps establish baseline expression patterns that may be altered in pathological states; (2) When combined with phospho-specific antibody data, these studies have revealed that differential phosphorylation patterns correlate with SMAD2 stability and signaling outcomes ; (3) The understanding that linker region phosphorylation by kinases like NLK promotes SMAD2 degradation provides insight into potential therapeutic targets for modulating TGF-β signaling intensity in diseases like fibrosis and cancer ; (4) The relationship between C-terminal phosphorylation (activating) and linker region phosphorylation (often inhibitory) elucidates how cross-talk between signaling pathways fine-tunes SMAD2 function; (5) Alterations in the balance between total SMAD2 levels and specific phosphorylation events may serve as biomarkers for disease progression or treatment response. This integrated perspective allows researchers to contextualize their experimental findings within broader disease mechanisms and potentially identify novel therapeutic approaches targeting specific aspects of SMAD2 regulation.

What are the recommended storage and handling conditions for maintaining SMAD2 (Ab-220) Antibody activity?

For optimal maintenance of SMAD2 (Ab-220) Antibody activity, researchers should adhere to the following storage and handling protocols: (1) Store the antibody at -20°C for long-term preservation as recommended by manufacturers ; (2) For short-term use, storage at 4°C is acceptable but should be limited to 1-2 weeks ; (3) Avoid repeated freeze-thaw cycles by aliquoting the antibody into single-use volumes upon receipt; (4) When working with the antibody, keep it on ice and return to appropriate storage promptly; (5) The antibody is supplied at 1.0 mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, with 150mM NaCl, 0.02% sodium azide, and 50% glycerol , and this formulation should be maintained; (6) When diluting for applications, use fresh buffers free from microbial contamination; (7) Avoid exposure to strong light or oxidizing agents. Following these guidelines ensures maintenance of antibody specificity and sensitivity across multiple experimental applications.

What is the recommended protocol for using SMAD2 (Ab-220) Antibody in co-immunoprecipitation experiments?

For co-immunoprecipitation experiments using SMAD2 (Ab-220) Antibody, researchers should follow this optimized protocol: (1) Prepare cell lysates in non-denaturing lysis buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, with freshly added protease and phosphatase inhibitors); (2) Clear lysates by centrifugation at 12,000g for 15 minutes at 4°C; (3) Pre-clear lysate with Protein A/G beads for 1 hour at 4°C; (4) Incubate 1-2mg of pre-cleared lysate with 2-5μg of SMAD2 (Ab-220) Antibody overnight at 4°C with gentle rotation; (5) Add 40μl of Protein A/G beads and incubate for 2-4 hours at 4°C; (6) Wash immunoprecipitates 4-5 times with lysis buffer containing reduced detergent (0.1% NP-40); (7) Elute bound proteins by boiling in SDS-PAGE sample buffer for 5 minutes; (8) Analyze by Western blotting using antibodies against suspected interaction partners. For studying phosphorylation-dependent interactions, include phosphatase inhibitors throughout the procedure and consider parallel immunoprecipitations with phospho-specific SMAD2 antibodies for comparison.